Disclosure Form: Eric Hoffman

First Page		Document Content
Muscular dystrophy Cytoskeleton Dystrophin Pharmaceutical industry Conflict of interest National Institutes of Health Biology Medicine Health		Disclosure Form: Eric Hoffman Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 45,20 KB Share Document on Facebook

	How to find which exon or exons to skip. There is an easy way to find the exon or exons which have to be skipped for your son, if you know the mutation in his dystrophin gene – deletion, duplication, or premature stop. DocID: 1sVjc - View Document
	Widespread Muscle Expression of an AAV9 Human Mini-dystrophin Vector After Intravenous Injection in Neonatal Dystrophin-deficient Dogs DocID: 1sgoe - View Document
	Research Review No. 97. Mice with Exon 2 Duplication. The Studies: The authors of this study note that around 11% of cases of Duchenne Muscular Dystrophy (DMD) are due to a duplication in the dystrophin gene (1). Of th DocID: 1reMl - View Document
	Phase 4: Variant prioritisation Even with sound experimental design and variant filtering protocols, whole exome sequencing studies often still produce many more candidates than can be verified experimentally. While pos DocID: 1r6r6 - View Document
	Research Review No. 88. Recent exciting new Developments; A general oveview. The Studies: DocID: 1qUta - View Document